COVID-19 Updates

Date: February 21, 2022 Issue #:  1644Summary:  The IV antiviral drug remdesivir (Veklury – Gilead) has been available for treatment of COVID-19 in hospitalized patients since 2020. Now, the FDA has approved remdesivir for treatment of mild to moderate COVID-19 in outpatients ≥12 years old who weigh ≥40 kg and are at high risk for progression to severe disease, including hospitaliz ation or death; they also issued an Emergency Use Authorization (EUA) allowing its use in any other high-risk outpatient who weighs ≥3.5 kg.
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: Tags: Comirnaty COVID-19 nirmatrelvir Paxlovid remdesivir Ritonavir sotrovimab Spikevax Vaxzevria Viklury Source Type: research